TherapeuticsMD, Inc. (NASDAQ:TXMD) Short Interest Up 26.4% in October

TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large increase in short interest in the month of October. As of October 31st, there was short interest totalling 29,700 shares, an increase of 26.4% from the October 15th total of 23,500 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 13,700 shares, the short-interest ratio is currently 2.2 days.

TherapeuticsMD Stock Down 4.1 %

TXMD stock opened at $1.40 on Friday. TherapeuticsMD has a twelve month low of $1.36 and a twelve month high of $3.07. The business’s 50-day moving average price is $1.61 and its 200-day moving average price is $1.78.

Institutional Trading of TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. Institutional investors own 30.74% of the company’s stock.

Analysts Set New Price Targets

Separately, StockNews.com started coverage on shares of TherapeuticsMD in a report on Friday. They set a “hold” rating on the stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.